WallStreetZenWallStreetZen

NASDAQ: DRTS
Alpha Tau Medical Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DRTS

Based on 1 analyst offering 12 month price targets for Alpha Tau Medical Ltd

Min Forecast
$9.00+188.46%
Avg Forecast
$9.00+188.46%
Max Forecast
$9.00+188.46%

Should I buy or sell DRTS stock?

Based on 1 analyst offering ratings for Alpha Tau Medical Ltd.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DRTS stock forecasts and price targets.

DRTS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-29

1 of 1

Forecast return on equity

Is DRTS forecast to generate an efficient return?

Company
-37.06%
Industry
89.18%
Market
66.92%
DRTS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DRTS forecast to generate an efficient return on assets?

Company
-26.94%
Industry
25.01%
DRTS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DRTS earnings per share forecast

What is DRTS's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.46
Avg 2 year Forecast
-$0.45
Avg 3 year Forecast
-$0.33

DRTS revenue forecast

What is DRTS's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$1.3M
Avg 2 year Forecast
$15.7M

DRTS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DRTS$3.12$9.00+188.46%Buy
PRQR$2.04$8.14+299.17%Strong Buy
MNPR$35.78$62.00+73.28%Strong Buy
SLS$2.19N/AN/A
TVRD$23.33$60.67+160.04%Strong Buy
View Top Biotech Stocks

Alpha Tau Medical Stock Forecast FAQ

Is Alpha Tau Medical Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DRTS) stock is to Buy DRTS stock.

Out of 1 analyst, 0 (0%) are recommending DRTS as a Strong Buy, 1 (100%) are recommending DRTS as a Buy, 0 (0%) are recommending DRTS as a Hold, 0 (0%) are recommending DRTS as a Sell, and 0 (0%) are recommending DRTS as a Strong Sell.

If you're new to stock investing, here's how to buy Alpha Tau Medical stock.

What is DRTS's earnings growth forecast for 2025-2027?

(NASDAQ: DRTS) Alpha Tau Medical's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.23%.

Alpha Tau Medical's earnings in 2025 is -$31,750,000.On average, 3 Wall Street analysts forecast DRTS's earnings for 2025 to be -$32,375,062, with the lowest DRTS earnings forecast at -$33,078,868, and the highest DRTS earnings forecast at -$30,967,451. On average, 3 Wall Street analysts forecast DRTS's earnings for 2026 to be -$31,439,001, with the lowest DRTS earnings forecast at -$32,375,062, and the highest DRTS earnings forecast at -$29,559,839.

In 2027, DRTS is forecast to generate -$23,225,588 in earnings, with the lowest earnings forecast at -$25,337,005 and the highest earnings forecast at -$21,114,171.

What is DRTS's revenue growth forecast for 2026-2027?

(NASDAQ: DRTS) Alpha Tau Medical's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 128.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.43%.

Alpha Tau Medical's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast DRTS's revenue for 2026 to be $88,679,518, with the lowest DRTS revenue forecast at $88,679,518, and the highest DRTS revenue forecast at $88,679,518.

In 2027, DRTS is forecast to generate $1,105,678,755 in revenue, with the lowest revenue forecast at $1,105,678,755 and the highest revenue forecast at $1,105,678,755.

What is DRTS's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: DRTS) forecast ROA is -26.94%, which is lower than the forecast US Biotechnology industry average of 25.01%.

What is DRTS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DRTS price target, the average DRTS price target is $9.00, with the highest DRTS stock price forecast at $9.00 and the lowest DRTS stock price forecast at $9.00.

The Wall Street analyst predicted that Alpha Tau Medical's share price could reach $9.00 by Apr 29, 2026. The average Alpha Tau Medical stock price prediction forecasts a potential upside of 188.46% from the current DRTS share price of $3.12.

What is DRTS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: DRTS) Alpha Tau Medical's current Earnings Per Share (EPS) is -$0.45. On average, analysts forecast that DRTS's EPS will be -$0.46 for 2025, with the lowest EPS forecast at -$0.47, and the highest EPS forecast at -$0.44. On average, analysts forecast that DRTS's EPS will be -$0.45 for 2026, with the lowest EPS forecast at -$0.46, and the highest EPS forecast at -$0.42. In 2027, DRTS's EPS is forecast to hit -$0.33 (min: -$0.36, max: -$0.30).

What is DRTS's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: DRTS) forecast ROE is -37.06%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.